Interferon beta-1b biosimilar - Proteos biotech

Drug Profile

Interferon beta-1b biosimilar - Proteos biotech

Latest Information Update: 06 Jul 2015

Price : $50

At a glance

  • Originator Proteos biotech
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Multiple sclerosis

Most Recent Events

  • 06 Jul 2015 Discontinued for Multiple sclerosis in Spain (SC) (Proteos biotech pipeline, July 2015)
  • 05 Jun 2015 Early research in Multiple sclerosis in Spain (SC) (Proteos biotech product pipeline, June 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top